Abbisko's Pimicotinib Wins FDA Approval, Extending Global TGCT Franchise

Abbisko Therapeutics has received US market approval for Pimjetmi (pimicotinib), its oral CSF-1R inhibitor, for adult patients with symptomatic tenosynovial giant cell tumour (TGCT) where surgical resection may cause worsening functional limitation or severe complications. It is the fourth marketing authorisation for the molecule after China, Canada and Switzerland, and the first Abbisko-discovered asset to reach US patients, with the US, Canadian and Swiss filings reviewed through Project Orbis.

The approval rests on the Phase III MANEUVER study, where pimicotinib achieved an objective response rate of 56% versus 3% for placebo at week 25 by blinded independent review, with statistically significant and clinically meaningful improvements in range of motion, physical function and pain, and long-term follow-up showing 77% of week-25 responders maintaining benefit a further 12 months later.

Under the 2023 licence with Merck KGaA worth up to USD 605.5 million, Abbisko has already received USD 13.52 million in milestone and first-quarter royalty payments and will collect USD 20 million on first US commercial sale, plus double-digit royalties on global net sales, validating a China-originated discovery-to-global-commercialisation model.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details